8-K: Orthofix Reports Strong Q4, FY25 Results; Boosts 2026 Outlook

Orthofix Medical Inc. announced robust fourth quarter and full-year 2025 financial results, driven by strong performance in Bone Growth Therapies and U.S. Limb Reconstruction, alongside an optimistic 2026 financial guidance and updated three-year targets.

Summary

• Fourth quarter 2025 reported net sales were $219.9 million, including sales from M6 artificial cervical and lumbar discs, representing a 2.0% increase compared to Q4 2024.
• Non-GAAP pro forma net sales for Q4 2025 (excluding M6 discs) were $218.6 million, an increase of 3.1% on a pro forma constant currency basis compared to Q4 2024.
• Full-year 2025 reported net sales reached $822.3 million, a 2.9% increase compared to full-year 2024.
• Non-GAAP pro forma net sales for full-year 2025 (excluding M6 discs) were $811.9 million, an increase of 4.1% on a pro forma constant currency basis compared to full-year 2024.
• Reported net loss for Q4 2025 was $(2.2) million, or $(0.06) per share, significantly improved from $(29.1) million in Q4 2024.
• Reported net loss for full-year 2025 was $(92.2) million, or $(2.33) per share, improved from $(126.0) million in full-year 2024.
• Non-GAAP pro forma adjusted EBITDA for Q4 2025 was $29.2 million, or 13.4% of pro forma net sales, an increase of $5.3 million compared to Q4 2024.
• Non-GAAP pro forma adjusted EBITDA for full-year 2025 was $85.9 million, or 10.6% of non-GAAP pro forma net sales, up from $67.4 million (8.4% of reported net sales) in 2024.
• The company generated $16.8 million in free cash flow in Q4 2025, contributing to positive full-year 2025 free cash flow of $3.1 million (excluding M6-related restructuring charges), achieving near breakeven overall.
• Orthofix provided full-year 2026 guidance with net sales expected to range between $850 million to $860 million, implying approximately 5.5% year-over-year pro forma constant currency growth at the midpoint.
• Full-year 2026 non-GAAP adjusted EBITDA is expected to be $95 million to $98 million, representing 70 basis points of margin expansion at the midpoint compared to 2025.
• Free cash flow is expected to be positive for full-year 2026, excluding the impact of any potential legal settlements.
• The company updated its three-year financial targets (2026-2028) to a 6.5% to 7.5% net sales CAGR, mid-teens non-GAAP adjusted EBITDA as a percent of net sales for full-year 2028, and sustained positive free cash flow generation.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, demonstrating significant operational improvements, robust free cash flow generation, and positive forward-looking guidance, despite ongoing net losses.

Positives

• Achieved eighth consecutive quarter of adjusted EBITDA growth, demonstrating consistent operational improvement.
• Delivered robust free cash flow generation of $16.8 million in Q4 2025 and positive full-year 2025 free cash flow of $3.1 million (excluding M6-related restructuring charges).
• Global Spine Fixation net sales grew 10% on a constant currency basis in both Q4 and full-year 2025, including 5% U.S. Spine Fixation growth in Q4.
• Bone Growth Therapies (BGT) reported strong net sales growth of 7% in Q4 2025 and 6% for full-year 2025.
• U.S. Limb Reconstruction net sales increased by 8% in Q4 2025 and a significant 16% for full-year 2025.
• Non-GAAP pro forma adjusted EBITDA margin expanded by approximately 230 basis points in Q4 2025 compared to Q4 2024, indicating improved profitability.
• Provided optimistic 2026 financial guidance with expected net sales growth of 5.5% (pro forma constant currency at midpoint) and 70 basis points of adjusted EBITDA margin expansion.
• Updated three-year financial targets (2026-2028) affirm expectations for above-market net sales growth, expanding profitability, and sustained positive free cash flow generation.

Negatives

• Reported net losses of $(2.2) million in Q4 2025 and $(92.2) million for full-year 2025, although significantly narrowed from the prior year.
• The discontinuation of M6 product lines continues to impact reported sales, though pro forma figures are presented to exclude this effect.

Risks

• Ability to maintain operations to support customers and patients in the near-term and to capitalize on future growth opportunities.
• Risks associated with acceptance of surgical products and procedures by surgeons and hospitals.
• Development and acceptance of new products or product enhancements.
• Clinical and statistical verification of the benefits achieved via the use of products.
• Ability to adequately manage inventory.
• Ability to successfully optimize commercial channels.
• Success in defending legal proceedings brought against the company.
• Other risks and uncertainties more fully described in the Annual Report on Form 10-K for the year ended December 31, 2025.

Future Outlook

Orthofix projects full-year 2026 net sales between $850 million and $860 million, implying approximately 5.5% pro forma constant currency growth at the midpoint. Non-GAAP adjusted EBITDA is expected to be $95 million to $98 million, with a 70 basis point margin expansion. The company anticipates positive free cash flow for 2026, excluding potential legal settlements. Updated three-year targets (2026-2028) include a 6.5% to 7.5% net sales CAGR, mid-teens adjusted EBITDA margin by 2028, and sustained positive free cash flow.

Management Comments

• "The fourth quarter capped a year of meaningful operational progress for Orthofix." Massimo Calafiore, President and Chief Executive Officer.
• "Throughout 2025, BGT and U.S. Limb Reconstruction delivered strong performance, and the work we did to finalize our Spine commercial channel supported double-digit year-over-year constant currency net sales growth in our global Spine Fixation business." Massimo Calafiore.
• "This momentum contributed to our eighth consecutive quarter of adjusted EBITDA growth and a standout quarter of free cash flow generation, clear evidence of the strength of our focused initiatives and margin-enhancement efforts." Massimo Calafiore.
• "As we move into 2026, our priorities remain centered on expanding market penetration, accelerating adoption of enabling technologies, such as 7D FLASH Navigation, and advancing commercial execution." Massimo Calafiore.
• "With full-year contributions from the TRUELOK Elevate System and the FITBONE Bone Transport and Trochanteric Lengthening Nails, the planned second-half full launch of VIRATA, continued Spine commercial channel optimization, a renewed focus on advancing our Biologics portfolio, and sustained momentum across our Limb Reconstruction and BGT businesses, we believe the Company is well-positioned to deliver durable top-line growth, expanding margins, and strong free cash flow that supports long-term shareholder value." Massimo Calafiore.

Industry Context

StockSavvy.ai notes that Orthofix's focus on specialized solutions in spine and limb reconstruction, coupled with investments in enabling technologies like 7D FLASH Navigation, aligns with broader industry trends towards advanced surgical tools, digital healthcare, and an aging population requiring musculoskeletal care. The company's strategy to optimize commercial channels and leverage cross-selling opportunities positions it to capture market share in its addressable markets, which are projected to grow at 2-12% depending on the segment.

Comparison to Industry Standards

• The 7D FLASH Navigation system offers a 97.8% reduction in intraoperative radiation during adult degenerative spinal fusions, a 61% reduction in pediatric deformity spinal fusions, 98.8% accuracy with no pedicle breach, and is 94% faster than intraoperative CT-based systems, saving 63.6 minutes per case. These metrics highlight a significant competitive advantage in surgical efficiency and patient safety compared to traditional methods.
• Orthofix holds the #1 market position in Spine Bone Growth Therapies and #2 in Fracture Bone Growth Therapies, indicating strong leadership in these specific segments.
• The company's target of 6.5% to 7.5% net sales CAGR from 2026-2028 aims for above-market growth, given the weighted average market growth of ~4% to 5% for its addressable markets.

Legal Proceedings

• The company includes "Litigation and investigation-related costs" as a non-GAAP adjustment, which covers adverse or favorable legal judgments or negotiated legal settlements and certain related legal expenses.
• Costs incurred in relation to and as a result of a Board of Directors investigation that led to the departure of three former executive officers and associated charges are also adjusted for.
• Free cash flow guidance for 2026 explicitly excludes the impact of any potential legal settlements, indicating ongoing or potential future legal matters.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through durable top-line growth, expanding margins, and strong free cash flow, supported by positive guidance and long-term targets.
• Employees: Continued focus on operational excellence and growth opportunities, with a culture of execution and accountability.
• Customers (Surgeons & Hospitals): Continued innovation in products (e.g., TRUELOK Elevate, VIRATA, 7D FLASH Navigation) and comprehensive portfolio offerings aimed at improving clinical efficiencies and patient outcomes.
• Patients: Delivery of life-changing solutions and improved clinical outcomes through advanced medical technologies that heal musculoskeletal pathologies.

Next Steps

• Full-year contributions from the TRUELOK Elevate System and the FITBONE Bone Transport and Trochanteric Lengthening Nails.
• Planned second-half full launch of VIRATA Spinal Fixation System.
• Continued Spine commercial channel optimization.
• Renewed focus on advancing the Biologics portfolio.
• Expanding market penetration and accelerating adoption of enabling technologies like 7D FLASH Navigation.
• Conference call to discuss financial results on February 24, 2026.

Key Dates

Recommendation

The filing indicates a strong operational turnaround with significant improvements in adjusted EBITDA and free cash flow, coupled with positive guidance for 2026 and ambitious long-term targets. The company's strategic focus on high-growth product categories and enabling technologies, despite a recalibration of the three-year timeline, positions it for sustained profitable growth. The narrowing net loss and robust cash generation suggest a positive trajectory for investors.

Keywords

Medical Technology, Orthofix, OFIX, Spinal Implants, Bone Growth Therapies, Limb Reconstruction, Biologics, 7D FLASH Navigation, Financial Results, Earnings, Q4 2025, FY 2025, 2026 Guidance, Adjusted EBITDA, Free Cash Flow, MedTech